2022 San Antonio Breast Cancer Symposium Coverage

5 Key Takeaways From the 2022 San Antonio Breast Cancer Symposium

Kisqali Plus Hormonal Therapy More Effective Than Chemotherapy as First Treatment for Advanced-Stage Breast Cancer

Updated TAILORx Results Confirm Women With Intermediate Recurrence Score Can Skip Chemotherapy

Young Women Can Safely Pause Hormonal Therapy To Attempt Pregnancy

Benefits of Verzenio After Surgery for Early-Stage Breast Cancer Confirmed

Enhertu’s Benefits Confirmed for Metastatic, HER2-Positive Breast Cancer; Could Help Treat Early-Stage Disease

Cancer Culture: Art, Culture, and Equitable Development, with Beth Fairchild

Experimental Capivasertib Seems Promising for Advanced-Stage, Hormone Receptor-Positive, HER2-Negative Breast Cancer, with Nicholas Turner, MA, MRCP, PhD

GRASP: Helping Advocates Understand Research, Helping Researchers Understand Patients

2022 SABCS Key Take-Aways, with Stephanie Graff, MD

What I Get From Breastcancer.org Meetups, with Vanessa Onsurez

Enhertu Offers Better Overall Survival Than Kadcyla for Metastatic HER2-Positive Breast Cancer, with Sara Hurvitz, MD, FACP

Experimental Elacestrant Seems Effective for Breast Cancer Resistant to Other Types of Hormonal Therapy, with Virginia Kaklamani, MD, DSc

What Patients Want Doctors and Researchers to Know About Living With Metastatic Breast Cancer, with Christine Hodgdon and Stephanie Walker